{"id":"aegr-733-and-atorvastatin","safety":{"commonSideEffects":[{"rate":"null","effect":"Liver enzyme elevations"},{"rate":"null","effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AEGR-733 works by inhibiting the microsomal triglyceride transfer protein (MTP), which is involved in the assembly and secretion of very-low-density lipoproteins (VLDL) from the liver. Atorvastatin, on the other hand, inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. By inhibiting these enzymes, both drugs aim to lower cholesterol levels in the blood.","oneSentence":"AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor, and atorvastatin is a HMG-CoA reductase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:13.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT00474240","phase":"PHASE2","title":"AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-04","conditions":"Hypercholesterolemia","enrollment":157},{"nctId":"NCT00690443","phase":"PHASE2","title":"Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2008-05","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT00559962","phase":"PHASE2","title":"Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Hyperlipidemia","enrollment":260},{"nctId":"NCT00359281","phase":"PHASE2","title":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AEGR-733 and atorvastatin","genericName":"AEGR-733 and atorvastatin","companyName":"Aegerion Pharmaceuticals, Inc.","companyId":"aegerion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor, and atorvastatin is a HMG-CoA reductase inhibitor. Used for Hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}